NCT05602506View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

March 15, 2024

Study Completion Date

June 5, 2024

Conditions
HIV Infections
Interventions
DRUG

Biktarvy 50 mg/200 mg/25 mg film-coated tablets

The duration of the study treatment will be 48 weeks.

Trial Locations (1)

08036

Hospital Clinic i Provincial Barcelona, Barcelona

All Listed Sponsors
lead

Fundacion Clinic per a la Recerca Biomédica

OTHER